Management of Paranoid Schizophrenia with Suicide Risk and Command Hallucinations in a Religious Leader Post-COVID-19 Infection: A Case Report

Article Sidebar

PDF
Published: Jun 4, 2026
DOI: https://doi.org/10.55885/jchp.v6i2.963
Keywords:
Paranoid Schizophrenia, Suicide, Psychosocial Stress, Combination Therapy

Main Article Content

Gemilang Mutsaqqofa Arsyadana
Medical School, Universitas Muhammadiyah Surabaya, Jawa Timur, Indonesia
Era Catur Prasetya
Department of Psychiatry, Universitas Muhammadiyah Surabaya, Jawa Timur, Indonesia

Abstract

Paranoid schizophrenia is a severe mental disorder manifested by hallucinations and delusions. This case report presents the comprehensive management of a thirty three year old male religious leader diagnosed with paranoid schizophrenia, who exhibited a high psychiatric emergency risk of suicide attempts driven by command hallucinations. Clinical evaluation revealed that the exacerbation of psychotic symptoms was triggered by the interaction between neurobiological vulnerability post coronavirus infection and chronic psychosocial stress due to severe financial debt. The patient displayed somatic symptoms, panic attacks, and massive suicidal ideation. Combination pharmacotherapy using chlorpromazine and risperidone proved effective in reducing positive symptoms and acute agitation during the stabilization phase. Nevertheless, the prognosis is considered poor due to persistent environmental stressors including family conflicts. A holistic approach involving psychoeducation is absolutely necessary to prevent relapse and mitigate fatal risks in the future.

Article Details

How to Cite
Arsyadana, G. M., & Prasetya, E. C. . (2026). Management of Paranoid Schizophrenia with Suicide Risk and Command Hallucinations in a Religious Leader Post-COVID-19 Infection: A Case Report. Journal of Community Health Provision, 6(2), 337-345. https://doi.org/10.55885/jchp.v6i2.963
Issue
Vol. 6 No. 2 (2026): Journal of Community Health Provision
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

References

Astill Wright, L., McElroy, E., Barawi, K., Roberts, N. P., Simon, N., Zammit, S., & Bisson, J. I. (2023). Associations among psychosis, mood, anxiety, and posttraumatic stress symptoms: A network analysis. Journal of Traumatic Stress, 36(2), 385-396. https://doi.org/10.1002/jts.22916

Awad, A. G., & Voruganti, L. N. (2008). The burden of schizophrenia on caregivers: a review. Pharmacoeconomics, 26(2), 149-162. https://doi.org/10.2165/00019053-200826020-00005

Berman, A. L., & Silverman, M. M. (2020). Near term suicide risk assessment: A commentary on the clinical relevance of protective factors. Archives of suicide research, 24(sup2), S370-S380. https://doi.org/10.1080/13811118.2019.1612804

Brown, E., Gray, R., Monaco, S. L., O'Donoghue, B., Nelson, B., Thompson, A., ... & McGorry, P. (2020). The potential impact of COVID-19 on psychosis: a rapid review of contemporary epidemic and pandemic research. Schizophrenia research, 222, 79-87. https://doi.org/10.1016/j.schres.2020.05.005

Caponnetto, P., Benenati, A., & Maglia, M. G. (2021). Psychopathological impact and resilient scenarios in inpatient with schizophrenia spectrum disorders related to Covid physical distancing policies: A systematic review. Behavioral Sciences, 11(4), 49. https://doi.org/10.3390/bs11040049

Carlin, R. F., & Moon, R. Y. (2017). Risk factors, protective factors, and current recommendations to reduce sudden infant death syndrome: a review. JAMA pediatrics, 171(2), 175-180.

Carroll, S., Moon, Z., Hudson, J., Hulme, K., & Moss-Morris, R. (2022). An evidence-based theory of psychological adjustment to long-term physical health conditions: applications in clinical practice. Biopsychosocial Science and Medicine, 84(5), 547-559.

Challis, S., Nielssen, O., Harris, A., & Large, M. (2013). Systematic meta‐analysis of the risk factors for deliberate self‐harm before and after treatment for first‐episode psychosis. Acta Psychiatrica Scandinavica, 127(6), 442-454. https://doi.org/10.1111/acps.12074

Charlson, F. J., Ferrari, A. J., Santomauro, D. F., Diminic, S., Stockings, E., Scott, J. G., ... & Whiteford, H. A. (2018). Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophrenia bulletin, 44(6), 1195-1203. https://doi.org/10.1093/schbul/sby058

De Hert, M., Mazereel, V., Stroobants, M., De Picker, L., Van Assche, K., & Detraux, J. (2022). COVID-19-related mortality risk in people with severe mental illness: a systematic and critical review. Frontiers in psychiatry, 12, 798554. https://doi.org/10.3389/fpsyt.2021.798554

Defar, S., Abraham, Y., Reta, Y., Deribe, B., Jisso, M., Yeheyis, T., ... & Ayalew, M. (2023). Health related quality of life among people with mental illness: The role of socio-clinical characteristics and level of functional disability. Frontiers in public health, 11, 1134032. https://doi.org/10.3389/fpubh.2023.1134032

Deng, S. W., Xu, Q., Jiang, W. L., Hong, B., Li, B. H., Sun, D. W., & Yang, H. B. (2023). Efficacy and safety of blonanserin versus risperidone in the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials. BMC psychiatry, 23(1), 740. https://doi.org/10.1186/s12888-023-05240-7

Fowler, J. C. (2012). Suicide risk assessment in clinical practice: pragmatic guidelines for imperfect assessments. Psychotherapy, 49(1), 81. https://psycnet.apa.org/doi/10.1037/a0026148

Hao, F., Tan, W., Jiang, L. I., Zhang, L., Zhao, X., Zou, Y., ... & Tam, W. (2020). Do psychiatric patients experience more psychiatric symptoms during COVID-19 pandemic and lockdown? A case-control study with service and research implications for immunopsychiatry. Brain, behavior, and immunity, 87, 100-106. https://doi.org/10.1016/j.bbi.2020.04.069

Hawton, K., Lascelles, K., Pitman, A., Gilbert, S., & Silverman, M. (2022). Assessment of suicide risk in mental health practice: shifting from prediction to therapeutic assessment, formulation, and risk management. The Lancet Psychiatry, 9(11), 922-928.

Janiri, D., Doucet, G. E., Pompili, M., Sani, G., Luna, B., Brent, D. A., & Frangou, S. (2020). Risk and protective factors for childhood suicidality: a US population-based study. The Lancet Psychiatry, 7(4), 317-326.

Jauhar, S., Johnstone, M., & McKenna, P. J. (2022). Schizophrenia Lancet 399 (10323): 473–486.

Lee, J., Jung, K., Newman, E. G., Chow, E., & Chen, Y. (2025, April). Understanding Adolescents' Perceptions of Benefits and Risks in Health AI Technologies through Design Fiction. In Proceedings of the 2025 CHI Conference on Human Factors in Computing Systems (pp. 1-20).

Leucht, S., Schneider‐Thoma, J., Burschinski, A., Peter, N., Wang, D., Dong, S., ... & Davis, J. M. (2023). Long‐term efficacy of antipsychotic drugs in initially acutely ill adults with schizophrenia: systematic review and network meta‐analysis. World Psychiatry, 22(2), 315-324. https://doi.org/10.1002/wps.21089

Masika, A. K. (2025). A Conceptual Approach to Integrating Multidimensional Theories in Psychological Interventions for Schizophrenia. ShahidiHub International Journal of Education, Humanities & Social Science, 3(1), 18-33.

Minzenberg, M. J., Yoon, J. H., & Carter, C. S. (2008). Schizophrenia is a serious and lifelong mental disor-der that affects 1% of the population worldwide. It is characterized by a range of striking disturbances in mental functioning that are conceptualized as signs and symptoms that can be grouped into discrete cate. The American Psychiatric Publishing Textbook of Psychiatry, 407.

Misiak, B., Stramecki, F., Gawęda, Ł., Prochwicz, K., Sąsiadek, M. M., Moustafa, A. A., & Frydecka, D. (2018). Interactions between variation in candidate genes and environmental factors in the etiology of schizophrenia and bipolar disorder: a systematic review. Molecular neurobiology, 55(6), 5075-5100.

Mork, E., Walby, F. A., Harkavy-Friedman, J. M., Barrett, E. A., Steen, N. E., Lorentzen, S., ... & Mehlum, L. (2013). Clinical characteristics in schizophrenia patients with or without suicide attempts and non-suicidal self-harm-a cross-sectional study. BMC psychiatry, 13(1), 255. https://doi.org/10.1186/1471-244X-13-255

Nasim, R., Nawaz, S., & Nasim, M. T. (2025). The effects of antipsychotic drugs and non-pharmacological therapies on schizophrenia. Targets, 3(1), 10. https://doi.org/10.3390/targets3010010

Ockene, I. S., Hayman, L. L., Pasternak, R. C., Schron, E., & Dunbar-Jacob, J. (2002). Task force# 4—adherence issues and behavior changes: achieving a long-term solution. Journal of the American College of Cardiology, 40(4), 630-640.

Pisani, A. R., Murrie, D. C., & Silverman, M. M. (2016). Reformulating suicide risk formulation: from prediction to prevention. Academic Psychiatry, 40(4), 623-629. https://doi.org/10.1007/s40596-015-0434-6

Pompili, M. (2024). Assessment and management of suicide risk: what psychiatrists should know. International Review of Psychiatry, 36(7), 703-713. https://doi.org/10.1080/09540261.2023.2276898

Pompili, M., De Berardis, D., Dell’Osso, B., Forte, A., Innamorati, M., Rogante, E., ... & Amore, M. (2025). Suicide and suicidal behaviors: insight into clinical challenges and preventive measures. Expert Review of Neurotherapeutics, 25(9), 1011-1026. https://doi.org/10.1080/14737175.2025.2542764

Putri, S., Sansuwito, T., & Panduragan, S. L. (2024). Factors Contributing to The Relapse of Schizophrenia Patients After Recovery: An Update Narrative Review. Journal of Health Sciences and Epidemiology, 2(3), 139-146. https://doi.org/10.62404/jhse.v2i3.59

Rahmani, F., Roshangar, F., Gholizadeh, L., & Asghari, E. (2022). Caregiver burden and the associated factors in the family caregivers of patients with schizophrenia. Nursing Open, 9(4), 1995-2002. https://doi.org/10.1002/nop2.1205

Razali, S. M. (2010). Prevention of relapse and interventions for enhancing medication adherence in schizophrenia: An East Asian perspective. Asia‐Pacific Psychiatry, 2(2), 68-76. https://doi.org/10.1111/j.1758-5872.2010.00067.x

Rennie, C. E., & Dolan, M. C. (2010). The significance of protective factors in the assessment of risk. Criminal behaviour and mental health, 20(1), 8-22. https://doi.org/10.1002/cbm.750

Rössler, W., Salize, H. J., Van Os, J., & Riecher-Rössler, A. (2005). Size of burden of schizophrenia and psychotic disorders. European neuropsychopharmacology, 15(4), 399-409. https://doi.org/10.1016/j.euroneuro.2005.04.009

Roy, A., & Pompili, M. (2009). Management of schizophrenia with suicide risk. Psychiatric Clinics, 32(4), 863-883.

Schmitt, A., Falkai, P., & Papiol, S. (2023). Neurodevelopmental disturbances in schizophrenia: evidence from genetic and environmental factors. Journal of neural transmission, 130(3), 195-205. https://doi.org/10.1007/s00702-022-02567-5

Silverman, M. M., & Berman, A. L. (2014). Training for suicide risk assessment and suicide risk formulation. Academic Psychiatry, 38(5), 526-537. https://doi.org/10.1007/s40596-014-0200-1

Solmi, M., Seitidis, G., Mavridis, D., Correll, C. U., Dragioti, E., Guimond, S., ... & Cortese, S. (2023). Incidence, prevalence, and global burden of schizophrenia-data, with critical appraisal, from the Global Burden of Disease (GBD) 2019. Molecular psychiatry, 28(12), 5319-5327. https://doi.org/10.1038/s41380-023-02138-4

Stewart, I., & Lees-Deutsch, L. (2022). Risk assessment of self-injurious behavior and suicide presentation in the emergency department: An integrative review. Journal of emergency nursing, 48(1), 57-73. https://doi.org/10.1016/j.jen.2021.10.002

Stickley, A., Shirama, A., & Sumiyoshi, T. (2023). Financial debt, worry about debt and mental health in Japan. BMC psychiatry, 23(1), 761. https://doi.org/10.1186/s12888-023-05235-4

Świtaj, P., Anczewska, M., Chrostek, A., Sabariego, C., Cieza, A., Bickenbach, J., & Chatterji, S. (2012). Disability and schizophrenia: a systematic review of experienced psychosocial difficulties. BMC psychiatry, 12(1), 193. https://doi.org/10.1186/1471-244X-12-193

Taylor, P. J., Hutton, P., & Wood, L. (2015). Are people at risk of psychosis also at risk of suicide and self-harm? A systematic review and meta-analysis. Psychological medicine, 45(5), 911-926. https://doi.org/10.1017/S0033291714002074

Valdés-Florido, M. J., López-Díaz, Á., Palermo-Zeballos, F. J., Martínez-Molina, I., Martín-Gil, V. E., Crespo-Facorro, B., & Ruiz-Veguilla, M. (2020). Reactive psychoses in the context of the COVID-19 pandemic: clinical perspectives from a case series. Revista de psiquiatria y salud mental, 13(2), 90-94. https://doi.org/10.1016/j.rpsm.2020.04.009

Van Winkel, R., Stefanis, N. C., & Myin-Germeys, I. (2008). Psychosocial stress and psychosis. A review of the neurobiological mechanisms and the evidence for gene-stress interaction. Schizophrenia bulletin, 34(6), 1095-1105. https://doi.org/10.1093/schbul/sbn101

Velligan, D. I., Weiden, P. J., Sajatovic, M., Scott, J., Carpenter, D., Ross, R., & Docherty, J. P. (2010). Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines. Journal of Psychiatric Practice®, 16(5), 306-324.

Ventriglio, A., Gentile, A., Bonfitto, I., Stella, E., Mari, M., Steardo, L., & Bellomo, A. (2016). Suicide in the early stage of schizophrenia. Frontiers in psychiatry, 7, 116. https://doi.org/10.3389/fpsyt.2016.00116

Wahbeh, M. H., & Avramopoulos, D. (2021). Gene-environment interactions in schizophrenia: a literature review. Genes, 12(12), 1850. https://doi.org/10.3390/genes12121850

Zamanpoor, M. (2020). Schizophrenia in a genomic era: a review from the pathogenesis, genetic and environmental etiology to diagnosis and treatment insights. Psychiatric genetics, 30(1), 1-9.

Zhand, N., & Joober, R. (2021). Implications of the COVID-19 pandemic for patients with schizophrenia spectrum disorders: narrative review. BJPsych open, 7(1), e35. https://doi.org/10.1192/bjo.2020.157